A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors Clinical Trial

Official title:

A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-415S1 in Patients With Advanced Malignant Solid Tumor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05886374
• Other study ID #: 2022-415-00CH1
• Status: Recruiting
• Phase: Phase 1
• Start date: July 6, 2023
• Est. completion date: June 30, 2026

Study information

• Verified date: July 2023
• Source: Hutchmed
• Contact: Ronghua Zhang
• Phone: +86 1526711056
• Email: ronghuaz[@]hutch-med.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-415S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor.

Description:

This study is expected to enroll 36-81 patients, including 26-66 patients for dose escalation, additional 10-15 patients will be enrolled at the dose level of determined RP2D.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 81
• Est. completion date: June 30, 2026
• Est. primary completion date: May 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

All the following conditions must be met for enrollment:

1. Fully understand this study and voluntarily sign the ICF;

2. Dose escalation Patients with advanced malignant solid tumor confirmed by histopathology or cytology, who have failed, been intolerant or unavailable to, or have none standard treatment for various reasons; Dose expansion phase: Patients with advanced malignant solid tumor confirmed by histopathology or cytology, who have failed, been intolerant or unavailable to, or have none standard treatment for various reasons, carrying aberrant activating mutations in the KRAS pathway;

3. Presence of at least one measurable lesion (RECIST 1.1 criteria);

4. Eastern Cooperative Oncology Group (ECOG) performance status = 1 point;

5. Life expectancy = 12 weeks as judged by the investigator;

6. Male of childbearing potential and their heterosexual partners of childbearing potential must agree to use effective methods of contraception.

Exclusion Criteria:

A patient may not participate in this study if any of the following conditions apply:

1. Patients who priorly received SHP2 inhibitors;

2. Receiving the approved systemic antitumor treatment within 4 weeks prior to the first dose, including: chemotreatment, targeted treatment, immunization treatment, biological treatment, etc. (wash-out for 2 weeks for hormone treatment or traditional chinese medicine and chinese patent medicine with clear antitumor indications);

3. Have been in the treatment period of other interventional clinical studies (including small molecule chemicals and large molecule antibodies) within 4 weeks prior to the first dose. If participating in a non-interventional clinical study (eg, epidemiological study), you can enroll in this study; if already in the survival follow-up period of an interventional clinical study, you can enroll in this study.

4. Major surgery or radical radiotreatment (except palliative radiotreatment for metastases to bone lesions) within 4 weeks prior to first dose.

5. Central nervous system (CNS) malignant tumor or known CNS metastasis;

6. Having multiple factors that affect the absorption, distribution, metabolism or excretion of orally administered drugs (such as inability to swallow drugs, frequent vomiting, chronic diarrhoea, etc.);

7. Any other disease, metabolic abnormality, physical examination abnormal, or clinically significant laboratory test abnormality that, in the judgment of the investigator, would compromise patient compliance or give reason to suspect that the patient has a disease or condition that would compromise the interpretation of study results or place the patient at high risk.

Related Conditions & MeSH terms

• Advanced Malignant Solid Tumors
• Neoplasms

Intervention

Drug:
• HMPL-415S1
HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules

Locations

Country	Name	City	State
China	Zhongshan Hospital Fudan University	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Hutchmed

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety, tolerability, and determine the maximum tolerated dose (MTD) and/or RP2D of HMPL-415S1 as a single oral agent in advanced malignant solid tumor	Occurrence of Dose Limiting Toxicities (DLTs) During the DLT Observation Period	from Cycle 0Day1 up to Cycle1Day28 (each cycle is 28 days).
Secondary	To investigate the pharmacokinetic (PK) profile of oral HMPL-415S1	Plasma peak concentration of HMPL-415S1 (Cmax).	from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days).
Secondary	AUCinf (Cycle 0 ) of HMPL-415S1	AUCinf: area under the concentration vs. time curve from zero to infinity after single (first)dose.	from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days).
Secondary	AUC(0-tlast) (Cycle 0 ) of HMPL-415S1	AUC from time zero to the last data point.	from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days).
Secondary	Objective Response Rate (ORR)	Percentage of patients with Complete Response(CR) or Partial Response(PR) as the best response evaluated in accordance with RECIST 1.1.	From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years).
Secondary	Disease control rate (DCR)	the proportion of patients with CR or PR or stable disease (SD) as the best response, and the duration of SD needs to be =6 weeks.	From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years).
Secondary	uration of response (DoR)	as the time from the first appearance of CR or PR to PD or death for any reason (whichever comes first), in the patients with objective response.	From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years).
Secondary	Time to response (TTR)	the time from the first dose of HMPL-415S1 to the first objective response.	From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years).
Secondary	Progression-free survival (PFS)	time from the first dose of study treatment to PD or death for any reason, whichever comes first.	From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years).
Secondary	Overall survival (OS)	time from the first dose of study treatment to death for any reason.	From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years).